Close

Pfizer (PFE) Palbociclib Phase 2 Met Primary Endpoint

February 3, 2014 7:01 AM EST Send to a Friend
Pfizer Inc. (NYSE: PFE) announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login